Hydroxynefazodone

Hydroxynefazodone
Clinical data
Other namesOH-NEF
Pharmacokinetic data
Elimination half-life1.5–4 hours[1]
Identifiers
  • 2-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H32ClN5O3
Molar mass486.01 g·mol−1
3D model (JSmol)
  • CC(C1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl)O
  • InChI=1S/C25H32ClN5O3/c1-20(32)24-27-31(25(33)30(24)17-18-34-23-9-3-2-4-10-23)12-6-11-28-13-15-29(16-14-28)22-8-5-7-21(26)19-22/h2-5,7-10,19-20,32H,6,11-18H2,1H3
  • Key:VKGQYGXMUUBRBD-UHFFFAOYSA-N

Hydroxynefazodone is a phenylpiperazine compound and a major metabolite of the antidepressant nefazodone.[1][2][3] It has similar biological activity and a similar elimination half-life (1.5 to 4 hours)[1] to those of nefazodone, and may contribute significantly to its effects.[2][3]

  1. ^ a b c Golden RN, Dawkins K, Nicholas L (2017). "Trazodone and Nefazodone". In Schatzberg AF, Nemeroff CB (eds.). The American Psychiatric Association Publishing Textbook of Psychopharmacology (Fifth ed.). American Psychiatric Pub. pp. 460–. ISBN 978-1-58562-523-9.
  2. ^ a b Preskorn SH, Catterson ML (6 December 2012). "General Principles of Pharmacokinetics". In Preskorn SH, Stanga CY, Feighner JP, Ross R (eds.). Antidepressants: Past, Present and Future. Springer Science & Business Media. pp. 68–. ISBN 978-3-642-18500-7.
  3. ^ a b Davis R, Whittington R, Bryson HM (April 1997). "Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression". Drugs. 53 (4): 608–636. doi:10.2165/00003495-199753040-00006. PMID 9098663. S2CID 239077479.